Home > Cardiology > Amgen drug shaves 8% off risk of heart-failure event or heart death

Amgen drug shaves 8% off risk of heart-failure event or heart death


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
New England Journal of Medicine
Conference
AHA 2020
Reuters Health - 13/11/2020 - For patients with symptomatic chronic heart failure, treatment with the selective cardiac myosin activator omecamtiv mecarbil shaved two percentage points off the risk of having a heart-failure event or dying from cardiovascular causes, according to results of the GALACTIC-HF study. That primary outcome occurred in 37.0% of the 4,120 participants randomly assigned to the drug compared to 39.1% of the 4,112 who got a placebo, an 8% reduction. Despite the absolute difference of just 2.1%, the improvement was statistically significant (P=0.03), according to results unveiled at the American Heart Association (AHA) Scientific Sessions meeting and published in the New England Journal of Medicine. The research team, led by Dr. John Teerlink of the San Francisco Veterans Affairs Medical Center, in California, characterized the difference as "modest." Amgen, Cytokinetics and Servier paid for the study. The U.S. Food and Drug Admini...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on